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Form or Function?Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsW hen evaluating patients with stableischemic heart disease (SIHD) who donot have compelling symptoms, both
form (anatomy) and function (perfusion) inform our
decisions for or against revascularization. I ﬁnd that
the pathway to making these decisions vary widely
on the 2 sides of the Paciﬁc.
Why do we revascularize patients with SIHD? It is
appropriate for 1 of 2 reasons, or both. They are relief
of symptoms and avoidance of death or disability.
This is not a novel concept, and it is one to which
we all ascribe. We promulgate guidelines that say
this, and we more recently created Appropriate
Use Criteria (AUC) that implies that this is our goal.
Medicine, however, is a highly nuanced discipline,
and despite dramatic technological advances, many
of our decisions are hardly more than educated
guesses. Nonetheless, these guesses are what our
patients depend on. The operative word here
is “educated.” Educated does not always mean
evidence-based. Many of our decisions are driven by
collective or personal experience applied to each
individual patient. There was a time when guidelines
for revascularization were written as though we were
in possession of all the parameters of the patient’s
condition. The history and the anatomic and func-
tional explanations for that history are gathered, and
then we make a prognostic estimation of the out-
comes of various interventions or avoidance of
intervention. For some interventional cardiologists,
patients do come with all this information, having
had assessment of their anginal severity and its
response to medical therapy, stress perfusion imag-
ing, and coronary arteriography. From these data, we
are to make “appropriate” recommendations. Here, I
spell “appropriate” with a small a to indicate that
all that is appropriate is not in the AUC. Patients,however, do not appear de novo with all this infor-
mation. They start out with symptoms or screening
exercise tests or some other variable that sparks the
work-up. For our colleagues who do not perform in-
terventions and who increasingly inﬂuence the pa-
tients’ decisions, all the evidence is seldom at hand.
Someone must decide whether a stress test or perfu-
sion scan or angiogram should be performed. A highly
abbreviated version of the guideline for ischemic
heart disease goes like this: if symptoms exist and are
not well controlled, then proceed to revasculariza-
tion; if perfusion scans or other evidence suggest
high-risk ischemia, then proceed to revascularization;
otherwise, do not. We would like to believe that this
is all evidence-based, but have to admit that much is
unknown about our individual patient. For uncon-
trolled angina, the evidence is strongest. Revascu-
larization works most of the time. For the other
endpoint, the job is tougher. Ever since the COURAGE
(Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial and the trials that
followed, it has been hard to prove reduction of the
hard endpoints in the average patient in these trials.
Much has been learned from the trials, and both the
extent of ischemia and the burden of anatomic dis-
ease have been correlated with this second outcome.
The decision to proceed with revascularization in the
absence of limiting symptoms is, however, a contin-
uum and not a black and white one. Without doubt,
there are patients without symptoms who are being
saved by revascularization. But, how do we ﬁnd
them, and how do we avoid revascularization in those
whose prognosis will not be improved?
I was previously driven to opine on whether form
or function as applied to SIHD was more important?
The substudy of the COURAGE trial showed that
baseline burden of disease shown angiographically
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1527was a better prognostic marker than the degree of
stress-induced ischemia (1,2). That suggestion, be it
accurate or not, cheered this old angiographer. If the
anatomy can be identiﬁed noninvasively, would it
not be better than the nuclear scan (derisively
referred to by some as “unclear medicine”)?
We often talk about the different approaches on the
2 sides of the Atlantic, but now I want to look at dif-
ferences on the 2 sides of the Paciﬁc. The annual
conference of the Japanese Association of Cardiovas-
cular Intervention and Therapeutics was recently
chaired by its president, Dr. Takafumi Ueno. Dr. Ueno
had been a fellow with us at the Saint Joseph’s
Translational Research Institute in Atlanta, and it was
an honor to be asked to participate in his meeting and a
thrill to see Dr. Ueno rise to lead his department in
Fukuoka and the Japanese Interventional Society.
During the meeting, I heard a most interesting and
revealing abstract. Based on the improving results
from studies using fractional ﬂow reserve (FFR)
guidance, a Japanese registry has been initiated to
evaluate the outcome of patients with FFR values
above or below 0.80 undergoing revascularization or
not undergoing revascularization. The presentation
was in Japanese, but the slides were in English. The
data presented were the baseline ﬁndings because no
outcomes data have been evaluated. I was surprised to
see FFR values below 0.80 were found in <20%. Then
came the slide of the clinical features showing that
60% of these individuals were asymptomatic. How are
these patients getting to the cath lab? I approached the
presenter of this abstract with this question. He
responded, “We do a lot of coronary CTAs [computed
tomography angiograms], and we identify a lot of
‘signiﬁcant’ coronary lesions.” I have long been aware
of the complexity of performing nuclear scans in Japanwhere there is a high sensitivity to controlling radio-
isotopes. I ﬁrst became aware of the use of coronary
CTA in place of the nuclear scans in Japan when a
paper was submitted applying the AUC to the Japanese
patients (3). Most indications were “inappropriate”
because the AUC on the North American side of the
Paciﬁc requires documentation of ischemia, whereas
on the Japanese side, decisions are being made based
on noninvasive anatomic ﬁndings derived from CTA.
Has the CTA (my anatomic surrogate for the coronary
angiogram) become the thallium scan (our unclear
medicine) on this side of the Paciﬁc? Before we decide
to make CTA the routine noninvasive screen for sig-
niﬁcant coronary artery disease, we might consider
the downstream consequences of unnecessary angi-
ography and interventions. For all of us on both sides
of the Paciﬁc, we need more information about the
approaches to decision making in SIHD. The ongoing
ISCHEMIA trial (International Study of Comparative
Health Effectiveness with Medical and Invasive Ap-
proaches) will test whether the presence of signiﬁcant
ischemia will be a satisfactory guide for taking pa-
tients to the cath lab with plans for revascularization. I
had been among those wondering whether the
anatomic ﬁndings of CTA might be a better noninva-
sive screening method. As of now, it seems that
neither form (CTA) nor function (perfusion scanning)
have provided the perfect cost-effective guide to
revascularization decision making. To this end, efforts
to combine form and function continue on both sides
of the Atlantic and the Paciﬁc.
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